BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Daiichi Sankyo, Inc. 

U.S. Corporate Headquarters
Two Hilton Court
Parsippany  New Jersey  07054  U.S.A.
Phone: 973-944-2600 Fax: 973-359-2645


SEARCH JOBS



About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator.

The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world.

A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders.


This div will be replaced



 Key Statistics


Email:
Ownership:

Web Site: Daiichi Sankyo, Inc.
Employees: 3,000 in the U.S.
Symbol: 4568.t
 



Industry
Pharmaceutical






 Company News
Daiichi Sankyo, Inc. (4568.t) And Eli Lilly and Company (LLY): Heart Patients In England And Wales Offered More Choice Of Therapies As National Institute for Clinical Excellence (NICE) Extends Recommendations For Prasugrel 7/23/2014 11:01:12 AM
Portola Pharmaceuticals, Inc. Enters Into Clinical Collaboration Agreement With Daiichi Sankyo, Inc. (4568.t) For Phase 3 Studies Of Factor Xa Inhibitor Antidote, Andexanet Alfa, And Edoxaban 7/7/2014 12:35:34 PM
Pieris Achieves Milestone Payment In Daiichi Sankyo, Inc. (4568.t) Collaboration To Develop AnticalinĀ® Therapeutics 6/23/2014 8:51:22 AM
Sanford-Burnham Medical Research Institute And Daiichi Sankyo, Inc. (4568.t) Form AllianceTo Study Novel Drug Targets In Cardiovascular-Metabolic Diseases 5/21/2014 12:58:14 PM
MRC Technology And Daiichi Sankyo, Inc. (4568.t) Collaborate To Identify Novel Targets For Drug Discovery 5/14/2014 10:21:29 AM
Agendia BV Announces New Agreement With Daiichi Sankyo, Inc. (4568.t) To Support Oncology Drug Development 4/24/2014 7:58:18 AM
Ken Keller Named President, U.S. Commercial, Daiichi Sankyo, Inc. (4568.t) 4/18/2014 8:55:42 AM
Astellas Pharma Inc. (ALPMY) And Daiichi Sankyo, Inc. (4568.t) Form Compound Library Sharing Partnership 3/20/2014 10:13:49 AM
Provepharm Announces That Its Partner In Japan, Daiichi Sankyo, Inc. (4568.t) Has Filed An NDA For The Marketing Of The Methylene Blue Injection Medicinal Product In Japan, Made Out Of Proveblue® Methylene Blue Active Substance 3/19/2014 10:27:45 AM
Daiichi Sankyo, Inc. (4568.t) Pledges Bold Action On Ranbaxy Laboratories (RANBAXY.BO) Production Problems 1/31/2014 7:14:40 AM
12345678910...